NCT05743452 is a EARLY_PHASE1 clinical trial of GBR with CS@Mg in Alveolar Bone Loss, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

Who is sponsoring NCT05743452?

NCT05743452 is sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

What drugs are being tested in NCT05743452?

Interventions in NCT05743452: GBR with CS@Mg.

What condition does NCT05743452 study?

NCT05743452 studies Alveolar Bone Loss.

Is NCT05743452 still recruiting?

NCT05743452 is currently status unknown. Last updated 15 February 2023.

Last reviewed 2023-02-15 · How we verify

NCT05743452

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Trial on the Safety and Efficacy of Magnesium Doped Calcium Silicate 3d Alveolar Bone Repair Unit for Periodontal Bone Defects

Status unknown EARLY_PHASE1 Last updated 15 February 2023

What this trial tests

EARLY_PHASE1 trial testing GBR with CS@Mg in Alveolar Bone Loss in 5 participants. Status unknown.

Timeline

18 August 2022

Primary endpoint
1 December 2023

1 December 2023

Quick facts

Lead sponsor	Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase	EARLY_PHASE1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	5
Start date	18 August 2022
Primary completion	1 December 2023
Estimated completion	1 December 2023
Sites	1 location across China

Drugs / interventions tested

GBR with CS@Mg

Conditions studied

Alveolar Bone Loss — all drugs for Alveolar Bone Loss →

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Who can join

Adults 18 to 65, any sex, with Alveolar Bone Loss. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Horizontal bone width
Time frame: 24 weeks after operation
The width of buccal lingual alveolar ridge was measured 1 mm below the crest of alveolar ridge.
Evaluation of wound healing
Time frame: 2 weeks after operation
The wound healing evaluation scale was modified according to the indicators described by Lobene et al (1986) and will be used to evaluate the wound healing after surgery. The gingival tissue in the material implantation area was evaluated.

Sponsor's own description

The goal of this clinical trial is to test in height increment of alveolar bone and safety evaluation index. The main question it aims to answer are: • The safety and effectiveness of magnesium calcium silicate three-dimensional alveolar bone repair unit in the repair of periodontal bone defects Participants will be treated through Guided Bone Regeneration operation with calcium magnesium silicate three-dimensional alveolar bone repair unit.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Functional Scaffolds for Bone Tissue Regeneration: A Comprehensive Review of Materials, Methods, and Future Directions.
Todd EA, Mirsky NA, Silva BLG, Shinde AR, et al · · 2024 · cited 40× · PMID 39452579 · DOI 10.3390/jfb15100280

Verify or expand the search:

Other recruiting trials for Alveolar Bone Loss

Currently open trials in the same condition.

NCT07508033 — Evaluation of Stem Cell Exosomes Versus Platelet-Rich Fibrin in Tooth Extraction Socket Healing · Phase 1, PHASE2 · recruiting
NCT07375004 — Injectable PRF in Non-Surgical Periodontal Treatment · NA · active not recruiting
NCT07449806 — Assessment of Labial Plate Thickness After Immediate Implant Placement Using Two Different Xenografts in the Esthetic Zo · NA · recruiting
NCT07419269 — Comparison of Customized Allogenic Versus Autogenous Bone Block Graft for Alveolar Ridge Augmentation · NA · recruiting
NCT06887582 — Crestal Sinus Lifting in Periodontally-Compromised Patients Utilizing Autologous Dentin Graft · NA · active not recruiting

Other Second Affiliated Hospital, School of Medicine, Zhejiang University trials

Trials by the same sponsor.

NCT07445152 — Research on Construction and Verification of Multimodal Medical Imaging Large Model · not yet recruiting
NCT06775665 — A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population · not yet recruiting
NCT07533422 — Rescue Reatment of Helicobacter Pylori Based on Fecal Antimicrobial Resistance Gene Testing · NA · not yet recruiting
NCT07487285 — A Non-inferiority Study of Laser Combined With Ultrasonic Debridement Therapy (LCUDT) Versus Manual Combined With Ultras · NA · not yet recruiting
NCT07505186 — Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05743452 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital, School of Medicine, Zhejiang University
Last refreshed: 15 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05743452.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing